A composite bacterial preparation for treating atherosclerosis

Through the complex bacteria preparations of Lactobacillus plantarum, Lactobacillus paracasei and Enterobacter aerobic acid, combined with oligosaccharide protective agents, the treatment problem of atherosclerosis was solved, significantly reducing the serum cholesterol and low-density lipoprotein cholesterol levels in mice. , improve the high-density lipoprotein cholesterol level and achieve effective treatment of atherosclerosis.

CN116042486BActive Publication Date: 2024-11-08GAOYOU PEOPLES HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310145782.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-02-22
Publication Date
2024-11-08
Estimated Expiration
2043-02-22

AI Technical Summary

Technical Problem

Currently, there is a lack of effective early intervention methods for the treatment of atherosclerosis, especially Lactobacillus-based complex bacterial preparations have not yet appeared in related reports.

Method used

Provide a complex bacteria preparation, including Lactobacillus plantarum, Lactobacillus paracasei and Enterobacter aerobic bacteria, combined with oligosaccharides as lyophilized protective agents, to prepare a synergistic therapeutic artery by optimizing the combination and proportion of bacterial strains. Atherosclerosis medicine.

Benefits of technology

Significantly lower the serum total cholesterol and LDL cholesterol levels in mice, while increasing the high-density lipoprotein cholesterol levels, demonstrating the therapeutic effect of this complex bacteria preparation on atherosclerosis, and improving bacteria through oligosaccharide protective agents Survival rate of the species after lyophilization.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004089113920000051
    Figure BDA0004089113920000051
Patent Text Reader

Abstract

The present invention relates to a composite bacterial preparation for treating atherosclerosis, the preparation comprising composite bacteria and a freeze-drying protective agent, the composite bacteria comprising Lactobacillus plantarum, Lactobacillus paracasei and Enterobacter aerogenes, the weight ratio of Lactobacillus plantarum, Lactobacillus paracasei and Enterobacter aerogenes in the composite bacteria is (1-3): (1-3): (1-3), and the freeze-drying protective agent is an oligosaccharide. In the composite bacterial preparation prepared by the present invention, the freeze-drying survival rate of Lactobacillus plantarum, Lactobacillus paracasei and Enterobacter aerogenes is high, and the three strains in the composite bacterial preparation have a synergistic therapeutic effect on atherosclerosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of medicines, and in particular to a composite bacterial preparation for treating atherosclerosis. Background Art

[0002] Atherosclerosis (AS) is a common basic pathological change of various cardiovascular diseases. Cardiovascular disease (CVD) includes a series of heart and vascular diseases such as coronary heart disease (CHD), cerebrovascular disease, and peripheral arterial vascular disease. In recent years, with the change of dietary structure, the incidence of atherosclerosis in my country has increased year by year, accompanied by a trend of younger age. According to the "China Cardiovascular Disease Report 2013", there are currently 290 million cardiovascular disease patients in the country, including 270 million with hypertension, 2.5 million with myocardial infarction, and 4.5 million with heart failure. One in every five adults has cardiovascular disease. The above situation is becoming more and more serious with the aggravation of the aging of the population in my country. Finding simple and effective early intervention treatment methods for atherosclerosis is an urgent problem to be solved.

[0003] In the past, it was believed that hyperlipidemia was the direct cause of atherosclerosis. However, a large number of clinical studies have found that more than one-third of people with hyperlipidemia will not develop significant vascular atherosclerotic plaque-like lesions throughout their lives. With the gradual deepening of research on the "gut flora-metabolite-immune axis", the correlation between intestinal flora and extraintestinal organ diseases has also been recognized. The intestinal flora plays an important role in maintaining the health of the cardiovascular system and the occurrence of related diseases. Regulating the balance of intestinal microecology to prevent and treat atherosclerosis is a potential method for preventing and treating cardiovascular diseases.

[0004] Probiotics refer to a sufficient number of live microorganisms that can have a beneficial effect on the health of the host, including Lactobacillus, Bifidobacterium and certain yeasts. They can effectively regulate the composition of the host's intestinal flora, maintain the integrity of the intestinal mucosal barrier, and prevent the translocation of intestinal bacteria to the outside of the intestine and the occurrence of local inflammatory responses. The most noteworthy thing is that probiotics are low-cost and have no toxic side effects. They can avoid or reduce the use of statins and lipid-lowering drugs, and patients are more inclined to accept probiotic therapy. At present, probiotic therapy has been widely used in clinical children as an adjuvant treatment for acute infectious diarrhea, antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea, and its safety has been clinically verified.

[0005] Lactobacillus plantarum is a new type of lactobacillus that has attracted the attention of researchers in recent years. Compared with other lactobacilli, Lactobacillus plantarum is very resistant to gastric acid and bile, can enter the human intestine in a live state and successfully colonize, and has the strongest butyrate production ability among conventional lactobacilli, and has strong anti-inflammatory function. At present, the research on Lactobacillus plantarum mainly focuses on improving the intestinal inflammatory microenvironment and mucosal immunity.

[0006] So far, there are no reports that composite bacterial preparations containing Lactobacillus plantarum are effective in preventing or treating atherosclerotic diseases. Summary of the invention

[0007] To solve the above technical problems, the present invention includes the following aspects:

[0008] A first aspect of the present invention provides a composite bacterial preparation for treating atherosclerosis, the preparation comprising composite bacteria and a lyophilization protectant, the composite bacteria comprising Lactobacillus plantarum, Lactobacillus paracasei and Enterobacter aerogenes.

[0009] Preferably, the composite bacteria consists of Lactobacillus plantarum, Lactobacillus paracasei and Enterobacter aerogenes.

[0010] Preferably, the Lactobacillus plantarum is the Lactobacillus plantarum with a deposit number of CGMCC 1.12732.

[0011] Preferably, the Lactobacillus paracasei is the Lactobacillus paracasei with the deposit number of CGMCC 1.9089.

[0012] Preferably, the Enterobacter aerogenes is the Enterobacter aerogenes with a deposit number of CGMCC 1.10716.

[0013] Preferably, the weight ratio of the plant lactobacillus, the paracasei lactobacillus and the aerogenes enterobacter is (1-3): (1-3): (1-3). More preferably, the weight ratio of the plant lactobacillus, the paracasei lactobacillus and the aerogenes enterobacter is (1-2): (2-3): (1-2). Further preferably, the weight ratio of the plant lactobacillus, the paracasei lactobacillus and the aerogenes enterobacter is 1:2:1.

[0014] Preferably, the lyoprotectant is an oligosaccharide. More preferably, the oligosaccharide is selected from one or more of manno-oligosaccharides, xylooligosaccharides or isomaltooligosaccharides. Further preferably, the oligosaccharide is isomaltooligosaccharide.

[0015] Preferably, the weight ratio of the total amount of the composite bacteria to the lyophilization protective agent is 1:(1-5). More preferably, the weight ratio of the total amount of the composite bacteria to the lyophilization protective agent is 1:2.

[0016] The second aspect of the present invention provides a method for preparing the above-mentioned composite bacterial preparation, comprising the following steps:

[0017] (1) inoculating Lactobacillus plantarum, Lactobacillus paracasei and Enterobacter aerogenes into corresponding culture media, culturing at 37° C. for 12 hours, centrifuging, discarding the supernatant, and obtaining three types of bacterial sludge dry matter;

[0018] (2) Take the prescribed amount of dry matter of Lactobacillus plantarum, Lactobacillus paracasei and Enterobacter aerogenes, add the prescribed amount of freeze-drying protective agent, mix thoroughly, add an appropriate amount of purified water to completely dissolve the mixture, pre-freeze at -40°C for 12 hours, and freeze-dry to obtain a composite bacterial preparation.

[0019] Preferably, the inoculation amount of Lactobacillus plantarum, Lactobacillus paracasei and Enterobacter aerogenes in step (1) is 8%.

[0020] Preferably, the centrifugation condition in step (1) is centrifugation at 4°C for 15 minutes.

[0021] Preferably, in the step (1), the culture medium used for Lactobacillus plantarum and Lactobacillus paracasei is MRS liquid culture medium, and the culture medium used for Enterobacter aerogenes is LB liquid culture medium.

[0022] Preferably, in the step (2), the weight ratio of the dry matter of Lactobacillus plantarum, Lactobacillus paracasei and Enterobacter aerogenes mud is (1-3): (1-3): (1-3). More preferably, in the step (2), the weight ratio of the dry matter of Lactobacillus plantarum, Lactobacillus paracasei and Enterobacter aerogenes mud is (1-2): (2-3): (1-2). Further preferably, in the step (2), the weight ratio of the dry matter of Lactobacillus plantarum, Lactobacillus paracasei and Enterobacter aerogenes mud is 1:2:1.

[0023] Preferably, the weight ratio of the total amount of dry matter in the bacterial mud to the added lyophilization protective agent in step (2) is 1:(1-5). More preferably, the weight ratio of the total amount of dry matter in the bacterial mud to the added lyophilization protective agent in step (2) is 1:2.

[0024] Preferably, the lyoprotectant added in step (2) is an oligosaccharide. More preferably, the oligosaccharide is selected from one or more of manno-oligosaccharides, xylooligosaccharides or isomaltooligosaccharides. Further preferably, the oligosaccharide is isomaltooligosaccharide.

[0025] Preferably, the weight-volume ratio of the mixture to the added purified water in step (2) is 1:(3-10). More preferably, the weight-volume ratio of the mixture to the added purified water in step (2) is 1:5.

[0026] The third aspect of the present invention provides the use of the above-mentioned composite bacterial preparation in the preparation of a drug for treating atherosclerosis.

[0027] The fourth aspect of the present invention provides the use of the above-mentioned composite bacterial preparation in the preparation of a drug capable of lowering serum total cholesterol level, lowering serum low-density lipoprotein cholesterol level and / or increasing serum high-density lipoprotein cholesterol level.

[0028] Preferably, the present invention provides the use of the above-mentioned composite bacterial preparation in the preparation of a drug having the effects of simultaneously lowering serum total cholesterol and low-density lipoprotein cholesterol levels and increasing serum high-density lipoprotein cholesterol levels.

[0029] The technical effects produced by the present invention are:

[0030] The present invention obtains a composite bacteria preparation having a synergistic therapeutic effect on atherosclerosis by optimizing the bacterial species (preferably a combination of Lactobacillus plantarum, Lactobacillus paracasei and Enterobacter aerogenes) and the proportion of the composite bacteria. In addition, the inventor of the present invention unexpectedly discovered that the use of an oligosaccharide freeze-drying protective agent can significantly improve the survival rate of the composite bacteria after freeze-drying, thereby achieving long-term protection of the activities of Lactobacillus plantarum, Lactobacillus paracasei and Enterobacter aerogenes after freeze-drying. DETAILED DESCRIPTION

[0031] If not otherwise specified, the strain collection number of the plant lactobacillus (Lactobacillus plantarum) used in the embodiments of the present invention and the test examples is CGMCC 1.12732, the strain collection number of the Lactobacillus paracasei (Lactobacillus paracasei) used is CGMCC 1.9089, and the strain collection number of the Enterobacter aerogenes (Enterobacter aerogenes) used is CGMCC 1.10716, all of which are purchased from China General Microbial Culture Collection Administration Center (CGMCC).

[0032] Preparation Example 1

[0033] Lactobacillus plantarum was inoculated into MRS liquid culture medium at an inoculum amount of 8%, cultured at 37° C. for 12 h, centrifuged at 4° C. for 15 min, and the supernatant was discarded to obtain Lactobacillus plantarum bacterial mud dry matter.

[0034] Preparation Example 2

[0035] The Lactobacillus paracasei was inoculated into the MRS liquid culture medium at an inoculum amount of 8%, cultured at 37° C. for 12 h, centrifuged at 4° C. for 15 min, and the supernatant was discarded to obtain the Lactobacillus paracasei bacterial mud dry matter.

[0036] Preparation Example 3

[0037] Enterobacter aerogenes was inoculated into LB liquid culture medium at an inoculum size of 8%, cultured at 37°C under constant temperature anaerobic conditions for 12 hours, centrifuged at 4°C for 15 minutes, and the supernatant was discarded to obtain Enterobacter aerogenes bacterial sludge dry matter.

[0038] Example 1: Freeze-dried compound bacteria product L1

[0039] Three kinds of bacterial sludge were prepared according to the method of Preparation Example 1-3, 1g of Lactobacillus plantarum sludge, 2g of Lactobacillus paracasei sludge and 1g of Enterobacter aerogenes sludge were taken therefrom, 8g of oligosaccharide as a freeze-drying protective agent was added, and the mixture was mixed evenly, 5 times the volume of pure water was added to the above mixture, and after it was completely dissolved, it was pre-frozen at -40°C for 12h, and freeze-dried to obtain the freeze-dried product L1 of the composite bacteria of the present invention.

[0040] Example 2: Freeze-dried compound bacteria L2

[0041] Three kinds of bacterial sludge were prepared according to the method of Preparation Example 1-3, 2g of Lactobacillus plantarum sludge, 1g of Lactobacillus paracasei sludge and 1g of Enterobacter aerogenes sludge were taken therefrom, 8g of oligosaccharide as a freeze-drying protective agent was added, and the mixture was mixed evenly. Five times the volume of pure water was added to the above mixture, and after it was completely dissolved, it was pre-frozen at -40°C for 12h and freeze-dried to obtain the freeze-dried product L2 of the composite bacteria of the present invention.

[0042] Example 3: Freeze-dried compound bacteria L3

[0043] Three kinds of bacterial sludge were prepared according to the method of Preparation Example 1-3, 1g of Lactobacillus plantarum sludge, 1g of Lactobacillus paracasei sludge and 2g of Enterobacter aerogenes sludge were taken therefrom, 8g of oligosaccharide as a freeze-drying protective agent was added, and the mixture was mixed evenly, 5 times the volume of pure water was added to the above mixture, and after it was completely dissolved, it was pre-frozen at -40°C for 12h, and freeze-dried to obtain the freeze-dried product L3 of the composite bacteria of the present invention.

[0044] Comparative Example 1, freeze-dried Lactobacillus plantarum C1

[0045] Prepare Lactobacillus plantarum slurry according to the method of Preparation Example 1, take 4 g of Lactobacillus plantarum slurry, add 8 g of oligosaccharide as a freeze-drying protective agent, mix well, add 5 times the volume of pure water to the above mixture, after complete dissolution, pre-freeze at -40°C for 12h, and freeze-dry to obtain the composite bacteria freeze-dried product C1 of the present invention.

[0046] Comparative Example 2: Freeze-dried compound bacteria C2

[0047] According to the method of Preparation Example 1-2, Lactobacillus plantarum sludge and Lactobacillus paracasei sludge were prepared respectively, 2 g of Lactobacillus plantarum sludge and 2 g of Lactobacillus paracasei sludge were taken, 8 g of oligosaccharide as a lyophilization protective agent was added, and the mixture was mixed evenly, 5 times the volume of pure water was added to the above mixture, and after it was completely dissolved, it was pre-frozen at -40°C for 12h, and freeze-dried to obtain the composite bacteria freeze-dried product C2 of the present invention.

[0048] Test Example 1: Determination of freeze-dried survival rate of the freeze-dried strains of the present invention after reconstitution

[0049] Take 1 g of the plant lactobacillus sludge, Lactobacillus paracasei sludge and Enterobacter aerogenes sludge prepared in Preparation Examples 1-3 respectively, add 2 g of four different lyophilization protectants (isomaltooligosaccharide, xylo-oligosaccharide, manno-oligosaccharide and sucrose) to each sludge, mix them evenly, add 5 times the volume of pure water to the above mixture, pre-freeze at -40 ° C for 12 h after complete dissolution, and freeze-dry to obtain freeze-dried products of three strains containing different lyophilization protectants.

[0050] The three strains of freeze-dried products containing different freeze-dried protective agents prepared above were taken separately, and an appropriate amount of purified water was added to restore the freeze-dried products to the mass before freeze-drying. After standing for 12 hours, the freeze-dried survival rates of Lactobacillus plantarum, Lactobacillus paracasei and Enterobacter aerogenes after the freeze-dried products were dissolved were measured. The determination of each experimental value in the test was the average value of 3 parallel experiments, and the freeze-dried survival rate was calculated according to the following formula:

[0051] Freeze-dried survival rate (%) = (number of viable bacteria after freeze-dried product reconstitution / number of viable bacteria before freeze-drying) * 100%

[0052] The freeze-dried survival rates of the freeze-dried products of the strains in each test group after reconstitution are shown in Table 1 below.

[0053] Table 1 Freeze-dried survival rate of different strains of freeze-dried products after reconstitution

[0054]

[0055] It can be seen from the above test that the use of the freeze-dried protective agent of the present invention, oligosaccharide isomaltooligosaccharide, oligosaccharide xylo-oligosaccharide and oligosaccharide manno-oligosaccharide can effectively improve the survival rate of the three strains of freeze-dried products, and the survival rate of 12h is all above 60%, among which oligosaccharide isomaltooligosaccharide has the best effect as a freeze-dried protective agent. In comparison, when sucrose, which is common in the art, is used as a freeze-dried protective agent, the survival rate of the three strains at 12h is less than 50%. It can be confirmed by the above test data that the oligosaccharide freeze-dried protective agent selected by the present invention has a long-term protective effect on the three strains.

[0056] Experimental Example 2: Effect of the composite bacterial preparation of the present invention on atherosclerosis model mice

[0057] 1. Test methods

[0058] Select 80 ApoE - / - Mice were fed with 180 g of high-fat diet (21% lard, 0.15% cholesterol and 78.85% basal diet) daily to establish an atherosclerosis (AS) model. - / - Endothelial damage, monocyte aggregation, and the appearance of foam cells were observed in the mouse aorta, suggesting the formation of an early AS model.

[0059] 60 mice with successful AS modeling were selected and randomly divided into 6 groups, namely, the model group, the composite bacterial agent group 1-3 of the present invention and the comparative example group 1-2, each group with 10 mice. Another 10 C57BL / 6N mice were taken as the normal group. The composite bacterial freeze-dried products prepared in Examples 1-3 and Comparative Examples 1-2 were added with appropriate amounts of purified water, respectively, and the freeze-dried products were restored to the mass before freeze-drying.

[0060] The composite bacterial agent 1-3 group of the present invention and the comparative example 1-2 group were respectively gavaged with the reconstituted bacterial solution of the freeze-dried product prepared in Examples 1-3 of the present invention and Comparative Example 1-2 at a dose of 20 g bacterial solution / kg body weight per day, and the model group and the normal group were respectively gavaged with the same dose of deionized water for 12 consecutive weeks. During the administration period, the normal group was fed with ordinary feed, and the other groups of mice continued to be fed with high-fat feed. After 12 weeks of drug intervention, serum samples of mice in each test group were taken, and the levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) in mouse serum were detected by a fully automatic biochemical analyzer.

[0061] 2. Test results

[0062] The effects of the freeze-dried composite bacteria of each test group of the present invention on the blood lipid level of mice are shown in Table 2.

[0063] Table 2 Blood lipid levels of mice in each experimental group (mmol / L)

[0064] Group TC LDL-C HDL-C Normal group 2.92±0.43 0.20±0.09 1.78±0.13 Model Group 55.46±7.38 15.92±2.07 0.42±0.08 Example 1 Group 28.41±3.72 3.95±0.91 0.92±0.17 Example 2 Group 35.29±3.81 6.47±1.27 0.82±0.11 Example 3 Group 36.64±4.02 6.02±1.33 0.78±0.21 Comparative Example 1 46.90±5.82 11.25±2.11 0.69±0.20 Comparative Example 2 44.25±4.97 10.24±1.85 0.66±0.18

[0065] ApoE - / - Mice are a commonly used animal model for studying AS. Studies have found that ApoE mice fed with ordinary diets - / -Compared with the normal group, high-fat feeding can significantly increase AS plaques, which is similar to the dietary dependence of human atherosclerotic heart disease. As shown in Table 2 above, compared with the normal group, the serum TC and LDL-C levels of the model group mice were significantly increased, and the HDL-C level was reduced. Compared with the model group, the TC and LDL-C levels of the mice in the 1-3 groups of the embodiments of the present invention were significantly reduced (with statistical differences), and the HDL-C level was increased, confirming that the composite bacterial agent of the present invention has a significant effect in treating atherosclerosis. Under the condition that the total bacterial content of the lyophilized product given is the same, the TC and LDL-C levels of the mice in the 1-3 groups of the embodiments of the present invention are significantly reduced (with statistical differences) compared with the 1-2 groups of the comparative examples, and the HDL-C level is increased, confirming that the three strains of the present invention have a synergistic effect on the treatment of atherosclerosis. It is worth noting that the serum TC and LDL-C levels of the mice given the composite bacterial preparation of Example 1 of the present invention were most significantly reduced, resulting in an excellent technical effect that was difficult to expect.

[0066] Although specific embodiments of the present invention have been described, it will be appreciated by those skilled in the art that various changes and modifications may be made to the present invention without departing from the scope or spirit of the present invention. Therefore, the present invention is intended to cover all such changes and modifications that fall within the scope of the appended claims and their equivalents.

Claims

1. A composite bacterial preparation for treating atherosclerosis, It is characterized in that The preparation comprises a composite bacterium and a freeze-drying protective agent, wherein the composite bacterium is Lactobacillus plantarum ( Lactobacillus plantarum )、Lactobacillus paracasei( Lactobacillus paracasei ) and Enterobacter aerogenes ( Enterobacter aerogenes ), the weight ratio of the plant lactobacillus, the paracasei lactobacillus and the aerogenes enterobacter in the composite bacteria is 1:2:1, the plant lactobacillus is the plant lactobacillus with a preservation number of CGMCC 1.12732, the paracasei lactobacillus is the paracasei lactobacillus with a preservation number of CGMCC 1.9089, and the aerogenes enterobacter is the aerogenes enterobacter with a preservation number of CGMCC 1.10716.

2. The composite bacterial preparation according to claim 1, It is characterized in that The lyophilization protective agent is oligosaccharide.

3. The composite bacterial preparation according to claim 2, It is characterized in that The oligosaccharide is selected from one or more of manno-oligosaccharide, xylooligosaccharide or isomaltooligosaccharide.

4. The composite bacterial preparation according to claim 3, It is characterized in that The oligosaccharide is isomaltooligosaccharide.

5. The composite bacterial preparation according to claim 4, It is characterized in that The weight ratio of the total amount of the composite bacteria to the freeze-dried protective agent is 1:(1-5).

6. A method for preparing the composite bacterial preparation according to any one of claims 1 to 5, It is characterized in that The following steps are involved: (1) Lactobacillus plantarum, Lactobacillus paracasei and Enterobacter aerogenes were inoculated into corresponding culture media respectively, cultured at 37°C for 12 hours, centrifuged, and the supernatant was discarded to obtain three types of bacterial sludge dry matter; (2) Take the prescribed amount of dry matter of Lactobacillus plantarum, Lactobacillus paracasei and Enterobacter aerogenes, add the prescribed amount of freeze-drying protective agent, mix thoroughly, add an appropriate amount of purified water to completely dissolve the mixture, pre-freeze at -40°C for 12 hours, and freeze-dry to obtain a composite bacterial preparation.

7. Use of the composite bacterial preparation according to any one of claims 1 to 5 in the preparation of a drug for treating atherosclerosis.